Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anlotinib - Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical

Drug Profile

Anlotinib - Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical

Alternative Names: AL-3818; ALTN; Anlotinib hydrochloride; FOCUS V

Latest Information Update: 10 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Developer Advenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group; Peking University People's Hospital
  • Class Antineoplastics; Cyclopropanes; Indoles; Quinolines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Nasopharyngeal cancer; Synovial sarcoma; Thyroid cancer
  • Phase II Cancer; Ewing's sarcoma; Gastrointestinal stromal tumours; Liver cancer; Neuroendocrine tumours; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma
  • Phase I/II Cervical cancer; Endometrial cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 20 Dec 2019 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Cholangiocarcinoma (Metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater), Colorectal cancer (Recurrent, Metastatic disease, Combination therapy, Inoperable/Unresectable), Gastric cancer (Recurrent, Metastatic disease, Combination therapy), Urogenital cancer (Metastatic disease, Late-stage disease, Combination therapy, Inoperable/Unresectable), Neuroendocrine tumours (Late-stage disease, Combination therapy) in China in January 2020 (NCT04207463)
  • 18 Dec 2019 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Head, neck and chest cancer (Late-stage disease, Metastatic disease, Combination therapy) in China in January 2020 (NCT04203719)
  • 29 Aug 2019 Chia Tai Tianqing Pharmaceutical plans a phase III trial (Combination therapy) for Non-small Cell Lung Cancer in China (NCT04073537)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top